The dramatic increase in survival of extremely premature infants has been associated with a growing population of individuals with neurodevelopmental disabilities. To date, clinical trials of neuroprotective agents in preterm infants have been limited, but new data suggest that erythropoietin might have important neuroprotective effects in these vulnerable infants.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mikkola, K. et al. Neurodevelopmental outcome at 5 years of age of a national cohort of extremely low birth weight infants who were born in 1996–1997. Pediatrics 116, 1391–1400 (2005).
Gonzalez, F. F. et al. Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke. Dev. Neurosci. 29, 321–330 (2007).
Juul, S. E. et al. Recombinant erythropoietin is neuroprotective in a novel mouse oxidative injury model. Dev. Neurosci. 30, 231–242 (2008).
Siren, A. L., Fasshauer, T., Bartels, C. & Ehrenreich, H. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 6, 108–127 (2009).
Neubauer, A. P., Voss, W., Wachtendorf, M. & Jungmann, T. Erythropoietin improves neurodevelopmental outcome of extremely preterm infants. Ann. Neurol. doi: 10.1002/ana.21977.
Sola, A., Wen, T. C., Hamrick, S. E. & Ferriero, D. M. Potential for protection and repair following injury to the developing brain: a role for erythropoietin? Pediatr. Res. 57, R110–R117 (2005).
Bierer, R., Peceny, M. C., Hartenberger, C. H. & Ohls, R. K. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics 118, e635–e640 (2006).
Brown, M. S., Eichorst, D., Lala-Black, B. & Gonzalez, R. Higher cumulative doses of erythropoietin and developmental outcomes in preterm infants. Pediatrics 124, e681–e687 (2009).
Newton, N. R., Leonard, C. H., Piecuch, R. E. & Phibbs, R. H. Neurodevelopmental outcome of prematurely born children treated with recombinant human erythropoietin in infancy. J. Perinatol. 19, 403–406 (1999).
Ohls, R. K. et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics 114, 1287–1291 (2004).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Limperopoulos, C. Neuroprotective effects of erythropoietin in preterm infants. Nat Rev Neurol 6, 301–302 (2010). https://doi.org/10.1038/nrneurol.2010.66
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2010.66
